Clinical Study of Recombinant Human Follitropin for Injection Assisted in Controlled Ovarian Hyperstimulation Assisted IVF-ET
试验速览
- 阶段
- 3 期
- 入组人数
- 252
- 试验地点
- 7
- 主要终点
- The total number of oocytes obtained during the start-up period
研究概览
简要总结
The aim of this study was to evaluate the efficacy and safety of domestic recombinant human follicle stimulating hormone (rhFSH) stimulating ovarian to promote follicular development before assisted reproductive technology, which was non-inferiority than that of the imported rhFSH.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 39 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age is more than 20 years old and less than 39 years old, married.
- •Applicable for ART controlled ovarian hyperstimulation, such as IVF/ET, ICSI, GIFT, ZIFT and so on.
- •Regular menstrual cycle (25-35 days).
- •18kg/m2≤BMI<30kg/m
- •The level of basic serum FSH <10IU / L in the 2nd-5th days of the menstrual cycle, the luteinizing hormone, estradiol and progesterone levels were normal.
- •The screening period or recent three months of vaginal ultrasound examination showed that the shape of bilateral ovarian and uterine size were normal and 5 ≤ number of basal antral follicle in unilateral ovarian <10, and follicular diameter <10 mm.
- •The in vitro fertilization and embryo transfer (IVF/ET) and (or) intracytoplasmic sperm injection (ICSI) technology were less than three times used prior to the reproductive treatment (provide copies of previous cases).
- •Volunteer to participate and sign informed consent.
排除标准
- •There are high risk of ovarian hyperstimulation syndrome (OHSS), such as the subject who has high response to gonadotropin in the previous ovarian hyperstimulation cycle, polycystic ovary syndrome (PCOS), the subject who has severe OHSS cancellation cycle.
- •Affect the outcome of pregnancy-related diseases (any one): untreated hydrosalpinx, untreated uterine polyps, untreated uterine infection, stage Ⅲ ~ IV endometriosis, ovarian cyst> 4cm , uterine fibroids diameter> 4cm, pelvic benign tumor> 4cm, pituitary tumors and malignant tumors of tissues and organs.
- •The subject has abnormal uterine bleeding.
- •Affect pregnancy-related endocrine and metabolic diseases (any one): hyperprolactinemia, thyroid disease (including hyperthyroidism, hypothyroidism), hyperandrogenism, adrenal dysfunction (including adrenal hyperfunction, adrenal cortical dysfunction).
- •The subject has severe liver and kidney dysfunction, which the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are 2.5 times higher than the upper limit of normal value, and serum creatinine (Cr) and urea nitrogen (BUN) are 2 times higher than the upper limit of normal value.
- •Severe heart disease, unstable angina pectoris, heart failure grade Ⅲ above, acute myocardial infarction and/or old myocardial infarction, hypertension diagnosed according to the 2010 edition of the Chinese Hypertension Prevention Guidelines.
- •The subject who have contraindications or allergic history for gonadotropin-releasing hormone agonists (GnRH-a), rFSH/human menopausal gonadotropin (hMG), human chorionic gonadotropin (hCG), progesterone drugs.
- •Positive HIV or syphilis.
- •The subject has alcoholism, smoking, drug abuse, bad drug abuse habits.
- •At least one of the spouses has received sperm donor or egg donor or PGD (genetic diagnosis before embryo transfer) and PGS (Preimplantation of embryos before genetic screening)。
- •The subject received clomiphene or gonadotropin therapy within 1 month before screening。
- •The subject was participated in last three months or are participating in other clinical research。
- •Patients with positive serum pregnancy test.
- •The investigators considered the subject inappropriate to be enrolled in this study.
研究组 & 干预措施
Recombinant Human Follitropin
Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
干预措施: Triptorelin for Injection (Drug)
Recombinant Human Follitropin
Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
干预措施: Recombinant Human Choriogonadotropin alfa Solution for Injection (Drug)
Recombinant Human Follitropin
Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
干预措施: Progesterone Soft Capsules (Drug)
Gonal-F
Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
干预措施: Triptorelin for Injection (Drug)
Gonal-F
Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
干预措施: Recombinant Human Choriogonadotropin alfa Solution for Injection (Drug)
Gonal-F
Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
干预措施: Progesterone Soft Capsules (Drug)
结局指标
主要结局
The total number of oocytes obtained during the start-up period
时间窗: On the days of ovum picking up (hCG trigger 36-38h)
Routine ova harvest to determine the number of obtained oocytes
次要结局
- The number of follicle-1(on the day of hCG day)
- The number of follicle-2(on the fifth day of rhFSH ovarian stimulation)
- Number of 2PN oocytes(Collected on the day of embryo transfer day after three days of ovum picking up.)
- Number of metaphase II oocytes(Collected on the day of embryo transfer day after three days of ovum picking up, which only collected during ICSI cycle.)
- Number of transferred embryos(Collected on the day of embryo transfer day after three days of ovum picking up.)
- Number of high quality embryos(Collected on the day of embryo transfer day after three days of ovum picking up.)
- Fresh cycle embryo implantation(Collected on the day of embryo transfer day after three days of ovum picking up.)
- rhFSH administered days and vials; administered total dose of rhFSH (IU)(Collected on the day of hCG day.)
- Serum E2 level(Collected on the day of hCG day.)
- High quality embryos rate(Collected on the day of embryo transfer day after three days of ovum picking up.)
- Fertilization rate(Collected on the day of embryo transfer day after three days of ovum picking up.)
- Fresh cycle embryo implantation rate(Collected between 28-35 days after embryo transfer.)
- Biochemical pregnancy rate(Collected between 14-16 days after embryo transfer.)
- Clinical pregnancy rate(Collected between 28-35 days after embryo transfer.)
- Continuous pregnancy rate(Collected after 12 weeks of embryo transfer.)
- The number of follicle-3(on the day of hCG day)
- The number of follicle-4(on the day of hCG day)
- Endometrium thickness (mm)(on the day of hCG)